AbbVie wins FDA nod for infusion treatment for advanced Parkinson’s disease

Vyalev is the first subcutaneous 24-hour continuous infusion of levodopa-based therapy for advanced Parkinson’s disease.
Article Attribution | Read More at Article Source
The post AbbVie wins FDA nod for infusion treatment for advanced Parkinson’s disease appeared first on RocketNews.